Introduction {#Sec1}
============

Natalizumab, a humanized anti-α4 integrin monoclonal antibody, has demonstrated efficacy in reducing relapse rates and disability worsening over 2 years among patients with relapsing-remitting multiple sclerosis (RRMS) in phase 3 studies that enrolled predominantly non-Asian patient populations \[[@CR1], [@CR2]\]. Results from the observational open-label Safety of TYSABRI Re-dosing and Treatment (STRATA) study showed that RRMS patients from the phase 3 clinical trials experienced continued reductions in annualized relapse rate (ARR), stability of Expanded Disability Status Scale (EDSS) scores, and low rates of confirmed EDSS worsening with natalizumab treatment after 4--5 years of follow-up \[[@CR3]\]. These results have been supported by results from studies conducted in the clinical practice setting \[[@CR4]--[@CR7]\].

More recently, the safety and efficacy of natalizumab in Japanese patients with RRMS was demonstrated in a 24-week phase 2 study \[[@CR8]\]. After 24 weeks of double-blind treatment, the adjusted ARR was significantly lower in natalizumab- than placebo-treated patients (0.53 vs. 1.73, *P* \< 0.001), and a significantly larger percentage of natalizumab- than placebo-treated patients were relapse-free (79% vs. 38%, *P* \< 0.001). From baseline to week 24, the mean EDSS score improved in the natalizumab group and worsened in the placebo group (change of −0.22 vs. 0.19, *P* = 0.019).

Here, we report results from the 2-year open-label extension study of patients who completed the phase 2 bridging study. The primary objective of this study was to evaluate the 2-year safety and tolerability of natalizumab in Japanese patients with RRMS. The secondary objective was to evaluate the 2-year efficacy of natalizumab in this patient population.

Methods {#Sec2}
=======

Study Design and Patient Population {#Sec3}
-----------------------------------

This study was a 2-year open-label extension study of patients who successfully completed part A or part B of the phase 2 bridging study \[[@CR8]\]. Briefly, Japanese patients (aged 18--65 years) were eligible for the phase 2 bridging study if, prior to enrollment, they had a diagnosis of RRMS as defined by the revised McDonald criteria \[[@CR9]\], ≥1 exacerbation within the previous year, and an EDSS score \[[@CR10]\] between 0.0 and 6.0 (inclusive) for part A and between 0.0 and 5.5 (inclusive) for part B. The use of concomitant immunosuppressive or immunomodulatory treatment (including interferon beta and long-term systemic corticosteroids) was not permitted at any time during the bridging or extension study; however, steroids were permitted in each study to treat on-study relapses.

In part A of the open-label bridging study, 12 patients received 300 mg natalizumab administered intravenously (IV) every 4 weeks for 24 weeks to assess pharmacodynamics and pharmacokinetics. Part B was a placebo-controlled double-blind study in which 94 patients were randomized (1:1) to receive 300 mg IV natalizumab or placebo every 4 weeks for 24 weeks, and the ARR and proportion of relapse-free patients were assessed. EDSS scores and changes from baseline were analyzed, although these variables were not pre-specified endpoints. The current study focused on the longer-term follow-up of subjects enrolled in parts A and B. To avoid potential bias, the assessment of efficacy included only the population randomized to blinded treatment in part B, while safety assessments included patients enrolled in both parts A and B.

Compliance with Ethics Guidelines {#Sec4}
---------------------------------

The study protocol was approved by the ethics committees at each participating site, and all patients provided written informed consent. The study was conducted in accordance with the International Conference on Harmonisation Guideline for Good Clinical Practice and the ethical principles outlined in the Declaration of Helsinki of 1964, as revised in 2013.

Assessment of Efficacy {#Sec5}
----------------------

For the open-label extension, clinical relapses were defined as new or recurrent neurological symptoms not associated with fever or infection and lasting for ≥24 h. Relapses were assessed throughout the 2 years of the extension study. EDSS scores were recorded by the examining neurologist, and because the EDSS was assessed every 12 weeks, the EDSS scores presented in this analysis were collected at week 120 of the extension study.

Assessment of Safety and Tolerability {#Sec6}
-------------------------------------

For the open-label extension, physical examinations were performed and vital signs were measured every 4 weeks, and neurological examinations and laboratory testing were conducted every 12 weeks. A 12-lead electrocardiogram was performed at week 24. Blood samples were taken at baseline and every 12 weeks thereafter to assess serum anti-natalizumab antibodies using a bridging enzyme-linked immunosorbent assay (ELISA) \[[@CR11]\]. Anti-JC virus (JCV) antibody testing for progressive multifocal leukoencephalopathy (PML) risk assessment was conducted every 24 weeks. Anti-JCV antibodies were detected using the STRATIFY JCV^®^ two-step ELISA (Focus Diagnostics, Cypress, CA, USA) \[[@CR12], [@CR13]\].

The immunogenicity population included all patients who received ≥1 infusion of study treatment, had a negative baseline antibody screening result, and had ≥1 post-baseline antibody assessment. Patients were considered persistently positive for anti-natalizumab antibodies if they had two positive results separated by ≥6--12 weeks. During the 24-week bridging study, the protocol was amended to include anti-JCV antibody testing at screening and week 24. Because this testing was begun when the study was already in progress, not all patients were tested for anti-JCV antibodies. During the open-label extension study, anti-JCV antibodies were tested at the open-label baseline (week 24 of the bridging study) and every 24 weeks thereafter.

Treatment-emergent adverse events (TEAEs) were monitored throughout the study. A TEAE was defined as any untoward medical occurrence regardless of its relationship to study medication. Severity (mild, moderate, or severe) and the possible relationship to study treatment (related or not related) were determined for each TEAE. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in death, was considered by the investigator to be life-threatening, required hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability or a congenital abnormality/birth defect, or was considered by the investigator to jeopardize the patient's well-being.

Statistical Analysis {#Sec7}
--------------------

All variables were analyzed using the intent-to-treat population, which included all patients who received ≥1 infusion of study treatment and had ≥1 post-baseline assessment of the variable of interest. In the extension study, efficacy variables (ARR, the proportion of relapse-free patients, and the change in EDSS score from baseline) were analyzed only for patients who had participated in the randomized double-blind placebo-controlled portion of the bridging study (part B). ARR was calculated as the total number of relapses experienced in a treatment group divided by the total number of days in the study multiplied by 365. Using a Poisson regression model, ARRs were adjusted for baseline relapse rate (i.e., the number of relapses in the year prior to screening for the 24-week bridging study) and reported with their 95% confidence intervals (CIs). EDSS scores and changes from baseline were summarized using descriptive statistics. Safety variables were assessed in patients enrolled in the extension study who had participated in either part A or B in the bridging study and were summarized using descriptive statistics.

Results {#Sec8}
=======

Patient Disposition {#Sec9}
-------------------

Ninety-seven patients who completed the 24-week double-blind treatment period of the bridging study were enrolled in the open-label extension, including 43 patients who had received placebo and 54 (10 from part A and 44 from part B) who had received natalizumab (Fig. [1](#Fig1){ref-type="fig"}). Overall, 39 patients (40%) completed the open-label extension, including 16 patients (37%) who had previously received placebo and 23 (43%) who had previously received natalizumab. Fifty-eight patients withdrew from the study (27 from the previously-on-placebo group and 31 from the previously-on-natalizumab group). The most common reasons for study withdrawal were withdrawal of consent (33 of 58 patients), investigator decision (8 of 58 patients), and TEAEs (8 of 58 patients).Fig. 1Study flow. *PD* pharmacodynamic, *PK* pharmacokinetic

Baseline characteristics were generally comparable between treatment groups; the mean (standard deviation \[SD\]) age of the patients was 37 (9) years, and 68% of patients were women. Overall, the mean (SD) time for participation in the open-label extension study (including patients who had withdrawn from the extension study) was 25.8 (11.0) months. Table [1](#Tab1){ref-type="table"} summarizes patient characteristics by treatment group. The mean (SD) number of doses of study treatment during the open-label extension was 24.9 (14.0), with all extension study patients receiving ≥1 dose of study treatment and \>90% of patients receiving ≥6 doses (Table [1](#Tab1){ref-type="table"}). In the overall population, the most frequently reported concomitant medications (excluding contrast medium) were loxoprofen (64%), PL^®^ granules (caffeine, salicylamide, paracetamol, and promethazine methylene; 39%), rebamipide (34%), and methylprednisolone (used to treat on-study relapses; 31%) (Table [1](#Tab1){ref-type="table"}).Table 1Extension study patient characteristics by treatment groupCharacteristicBridging study part ABridging study part BPreviously on natalizumab (*n* = 10)Previously on natalizumab (*n* = 44)Previously on placebo (*n* = 43)Time on study, mean ± SD, months^a^39.4 ± 11.820.2 ± 11.220.8 ± 12.5Time on study, *n* (%), months 0 to \<606 (14)9 (21) 6 to \<1203 (7)4 (9) 12 to \<181 (10)15 (34)2 (5) 18 to \<241 (10)3 (7)6 (14) 24 to \<3005 (11)9 (21) 30 to \<3608 (18)9 (21) 36 to \<4204 (9)4 (9) 42 to \<488 (80)00Natalizumab doses received, mean ± SD43.3 ± 12.722.5 ± 12.023.1 ± 13.2Natalizumab doses received, *n* (%) ≥110 (100)44 (100)43 (100) ≥610 (100)41 (93)37 (86) ≥1210 (100)36 (82)32 (74) ≥189 (90)25 (57)28 (65) ≥249 (90)17 (39)24 (56) ≥308 (80)15 (34)15 (35) ≥368 (80)10 (23)11 (26) ≥428 (80)1 (2)1 (2) ≥488 (80)0 (0)0 (0)Concomitant medications, *n* (%)^b^ Loxoprofen6 (60)30 (68)26 (60) Gadopentetate dimeglumine^c^0 (0)30 (68)27 (63) Gadodiamide^c^0 (0)21 (48)24 (56) PL granules^d^4 (40)18 (41)16 (37) Rebamipide3 (30)14 (32)16 (37) Methylprednisolone^e^2 (20)12 (27)16 (37)Antihistamines Famotidine2 (20)11 (25)15 (35) Fexofenadine1 (10)8 (18)11 (26)Influenza virus vaccine4 (40)12 (27)10 (23)Fingolimod^f^1 (10)11 (25)11 (26)Carbocisteine2 (20)7 (16)12 (28)Sennoside0 (0)11 (25)10 (23)Brotizolam4 (40)9 (20)7 (16)Meglumine gadopentetate^c^9 (90)6 (14)5 (12)*SD* standard deviation^a^Defined as 30 days^b^Includes medications taken by ≥20% of the overall population^c^Received as the diagnostic contrast medium for gadolinium enhancement^d^Caffeine, salicylamide, paracetamol, and promethazine methylene^e^For treatment of on-study relapses^f^The first dose of fingolimod was received after the last dose of natalizumab

Efficacy {#Sec10}
--------

Multiple sclerosis (MS) relapses and changes in disability were assessed in patients from part B of the bridging study. Relapse activity after 96 weeks in the extension study is summarized in Table [2](#Tab2){ref-type="table"}. The mean adjusted ARR was 0.30 (95% CI: 0.18--0.52) in patients who had previously received placebo and 0.13 (95% CI: 0.05--0.29) in patients who had previously received natalizumab (Fig. [2](#Fig2){ref-type="fig"}). Throughout 96 weeks of open-label natalizumab treatment, the proportions of patients with known relapse status who were relapse-free were 46% (12 of 26 patients) in the previously-on-placebo group and 55% (12 of 22 patients) in the previously-on-natalizumab group. Relapse-free status was unknown for an additional 17 previously-on-placebo and 22 previously-on-natalizumab patients, which includes patients who withdrew from the study and did not experience a relapse prior to withdrawal.Table 2Efficacy results: MS relapses after 2 years of treatmentEndpointPreviously on placebo (*n* = 43)Previously on natalizumab (*n* = 44)Patients with relapse, *n* (%)14 (33)10 (23)Patients with number of relapses, *n* (%) 0^a^29 (67)34 (77) 19 (21)8 (18) 23 (7)2 (5) 31 (2)0 (0) ≥41 (2)0 (0)Total relapses, *n*2712Total patient-years85.686.3Unadjusted ARR^b^0.320.14Patient-based ARR^c^0.400.16*ARR* annualized relapse rate, *MS* multiple sclerosis^a^Includes patients who withdrew from the study and did not experience a relapse prior to withdrawal^b^Total number of relapses during the study divided by the total number of patient-years in the study^c^Number of relapses for each patient divided by the number of years in the study for that patient Fig. 2Annualized relapse rate. \**P* \< 0.001 vs. placebo (Poisson regression model). ^†^Adjusted for baseline relapse rate. *CI* confidence interval

The mean change in EDSS score from baseline to week 120 was −0.03 in the previously-on-placebo group and −0.18 in the previously-on-natalizumab group.

Safety and Tolerability {#Sec11}
-----------------------

Most patients in both treatment groups experienced ≥1 TEAE, including 39 of 43 patients (91%) in the previously-on-placebo group and 53 of 54 patients (98%) in the previously-on-natalizumab group. The most frequently reported TEAEs by MedDRA System Organ Class (those occurring in \>30% of patients in both treatment arms) were infections and infestations, followed by nervous system and gastrointestinal disorders in both the previously-on-placebo group and the previously-on-natalizumab group (Table [3](#Tab3){ref-type="table"}). Sixteen of 43 patients (37%) in the previously-on-placebo group and 17 of 54 patients (31%) in the previously-on-natalizumab group experienced TEAEs that were considered related to study treatment (Table [4](#Tab4){ref-type="table"}).Table 3TEAEs occurring in ≥5% of patients in either treatment groupSOC and preferred term^a^, *n* (%)Previously on placebo (*n* = 43)Previously on natalizumab (*n* = 54)^b^Infections and infestations31 (72)33 (61) Nasopharyngitis23 (53)26 (48) Influenza6 (14)6 (11) Pharyngitis4 (9)4 (7) Cystitis3 (7)2 (4) Gastroenteritis2 (5)3 (6) Upper respiratory tract infection3 (7)1 (2)Nervous system19 (44)21 (39) MS relapse15 (35)15 (28) Headache4 (9)2 (4) Dizziness5 (12)0 (0)Gastrointestinal14 (33)23 (43) Diarrhea3 (7)5 (9) Constipation3 (7)4 (7) Dental caries2 (5)4 (7) Gastritis1 (2)4 (7) Stomatitis2 (5)3 (6) Nausea0 (0)3 (6)Skin and subcutaneous tissue12 (28)19 (35) Rash5 (12)4 (7) Eczema3 (7)5 (9)Musculoskeletal and connective tissue6 (14)15 (28) Arthralgia0 (0)4 (7) Back pain4 (9)0 (0) Musculoskeletal stiffness0 (0)4 (7) Myalgia0 (0)4 (7)Psychiatric7 (16)14 (26) Insomnia4 (9)6 (11) Depression1 (2)4 (7)Investigations4 (9)13 (24) WBC count increased1 (2)3 (6) Injury, poisoning, and procedural complications8 (19)11 (20)  Fall3 (7)2 (4)  Joint sprain3 (7)1 (2)Eye7 (16)7 (13) Dry eye1 (2)3 (6)General disorders and administration site conditions6 (14)7 (13) Pyrexia3 (7)3 (6)Reproductive system and breast3 (7)7 (13) Dysmenorrhea0 (0)3 (6)Respiratory, thoracic, and mediastinal6 (14)7 (13)Blood and lymphatic5 (12)4 (7) Iron deficiency anemia3 (7)0 (0)Hepatobiliary disorders1 (2)3 (6)Immune system6 (14)3 (6) Seasonal allergy4 (9)2 (4)Metabolism and nutrition disorders0 (0)3 (6)Renal and urinary disorders1 (2)3 (6)Surgical and medical procedures03 (6)Neoplasms benign, malignant, unspecified (including cysts and polyps)4 (9)2 (4)Ear and labyrinth disorders3 (7)1 (2)*MedDRA* Medical Dictionary for Regulatory Activities, *MS* multiple sclerosis, *SOC* system organ class, *TEAE* treatment-emergent adverse event, *WBC* white blood cell^a^As defined by MedDRA. Each patient was counted only once within each SOC/preferred term^b^Includes patients from part A and part B Table 4Treatment-related TEAEs occurring in ≥1 patient in either treatment groupSOC and preferred term^a^, *n* (%)^b^Previously on placebo (*n* = 43)Previously on natalizumab (*n* = 54)^c^Infections and infestations7 (16)4 (7) Mycoplasma infection2 (5)0 (0) Herpes zoster2 (5)0 (0) Gastroenteritis1 (2)0 (0) Nasopharyngitis1 (2)2 (4) Oral herpes1 (2)0 (0) Meningitis1 (2)1 (2) Vulvovaginal candidiasis1 (2)0 (0) Pharyngitis1 (2)0 (0) Cystitis1 (2)0 (0) Herpes virus infection0 (0)1 (2) Hordeolum0 (0)1 (2)Nervous system0 (0)3 (6) Transient global amnesia0 (0)1 (2) Headache0 (0)1 (2) Hypersomnia0 (0)1 (2)Gastrointestinal1 (2)4 (7) Stomatitis1 (2)1 (2) Esophageal ulcer0 (0)1 (2) Nausea0 (0)1 (2)  Gingival pain0 (0)1 (2)Hepatobiliary0 (0)2 (4) Hepatic function abnormal0 (0)2 (4)Skin and subcutaneous tissue3 (7)4 (7) Eczema1 (2)1 (2) Rash/rash pruritic2 (5)1 (2) Palmar erythema1 (2)0 (0) Skin lesion0 (0)1 (2) Hemorrhage subcutaneous0 (0)1 (2)Psychiatric2 (5)0 (0) Anxiety1 (2)0 (0) Depression1 (2)0 (0)Eye1 (2)0 (0) Abnormal sensation in eye1 (2)0 (0)Cardiac1 (2)0 (0) Sinus bradycardia1 (2)0 (0)Respiratory, thoracic, and mediastinal1 (2)1 (2) Oropharyngeal pain1 (2)0 (0) Interstitial lung disease0 (0)1 (2)Musculoskeletal and connective tissue1 (2)2 (4) Tenosynovitis1 (2)0 (0) Bursitis0 (0)1 (2) Musculoskeletal stiffness0 (0)1 (2) Myalgia0 (0)1 (2)Pregnancy, puerperium, and perinatal conditions1 (2)0 (0) Ectopic pregnancy1 (2)0 (0)Reproductive system and breast1 (2)1 (2) Menstruation irregular1 (2)1 (2)Investigations1 (2)4 (7) Blood alkaline phosphatase increased1 (2)1 (2) Gamma-glutamyltransferase increased0 (0)1 (2) Liver function test abnormal0 (0)1 (2) Alanine aminotransferase increased0 (0)1 (2) Aspartate aminotransferase increased0 (0)1 (2) Cholesterol increased0 (0)1 (2)General and administration site conditions3 (7)4 (7) Fatigue2 (5)1 (2) Pyrexia1 (2)1 (2) Infusion-related reaction1 (2)0 (0) Chest pain1 (2)0 (0) Feeling hot0 (0)1 (2) Injection site rash0 (0)1 (2)Blood and lymphatic2 (5)2 (4) Eosinophilia2 (5)1 (2) Lymphocytosis0 (0)1 (2) Neutropenia0 (0)1 (2)Immune system2 (5)0 (0) Anaphylactoid reaction2 (5)0 (0)Endocrine disorders0 (0)1 (2) Hypothyroidism0 (0)1 (2)*MedDRA* Medical Dictionary for Regulatory Activities, *SOC* system organ class, *TEAE* treatment-emergent adverse event^a^As defined by MedDRA^b^Some patients experienced multiple TEAEs^c^Includes patients from part A and part B

SAEs were experienced by 12 of 43 patients (28%) and 17 of 54 patients (31%) in the previously-on-placebo and previously-on-natalizumab groups, respectively. The most frequently reported SAE was MS relapse (Table [5](#Tab5){ref-type="table"}). Three previously-on-placebo patients (7%) and four previously-on-natalizumab patients (7%) experienced treatment-related SAEs. In the previously-on-placebo group, the three patients with treatment-related SAEs had meningitis and a mycoplasma infection, a skin rash, and an ectopic pregnancy, respectively. In the previously-on-natalizumab group, each of the following treatment-related SAEs was reported in one patient: esophageal ulcer and eosinophilia, interstitial lung disease, meningitis, and hypothyroidism. No deaths or cases of PML were reported during the open-label extension study.Table 5Serious AEs by treatment groupPreferred term^a^, *n* (%)^b^Previously on placebo (*n* = 43)Previously on natalizumab (*n* = 54)^c^MS relapse10 (23)7 (13)Arthralgia0 (0)1 (2)Asperger's disorder0 (0)1 (2)Bronchitis0 (0)1 (2)Central nervous system lesion0 (0)1 (2)Decreased appetite0 (0)1 (2)Enteritis0 (0)1 (2)Eosinophilia0 (0)1 (2)Hemorrhoids0 (0)1 (2)Hypothyroidism0 (0)1 (2)Inguinal hernia0 (0)1 (2)Interstitial lung disease0 (0)1 (2)Meningitis1 (2)1 (2)Esophageal ulcer0 (0)1 (2)Trigeminal neuralgia0 (0)1 (2)Uterine prolapse0 (0)1 (2)Ectopic pregnancy1 (2)0 (0)Mycoplasma infection1 (2)0 (0)Rash1 (2)0 (0)Schizophrenia1 (2)0 (0)Uterine cancer1 (2)0 (0)*AE* adverse event, *MedDRA* Medical Dictionary for Regulatory Activities, *MS* multiple sclerosis, *TEAE* treatment-emergent adverse event^a^As defined by MedDRA^b^Some patients experienced multiple TEAEs^c^Includes patients from part A and part B

Anti-Natalizumab Antibody Status {#Sec12}
--------------------------------

In the immunogenicity population, two patients in the previously-on-placebo group were persistently positive for anti-natalizumab antibodies. One of these patients experienced an infusion reaction, and both patients withdrew from the study. In addition, 1 patient was transiently positive for anti-natalizumab antibodies, with a positive result at week 12 and negative results at weeks 24, 36, and 48. In the previously-on-natalizumab group, no patients who were negative for anti-natalizumab antibodies during the 24-week bridging study became persistently positive for anti-natalizumab antibodies during the open-label extension study.

Anti-JCV Antibody Status {#Sec13}
------------------------

Overall, 69 of the 92 patients tested (75%) were anti-JCV antibody-positive at some point during the study. In the previously-on-natalizumab group, 17 of 25 patients (68%) and 37 of 51 patients (73%) were anti-JCV antibody-positive at baseline and overall, respectively. Similarly, 17 of 27 patients (63%) and 32 of 41 patients (78%) in the previously-on-placebo group were anti-JCV antibody-positive at baseline and overall, respectively.

Discussion {#Sec14}
==========

The findings of this open-label extension study of natalizumab in Japanese patients with RRMS support and extend the efficacy and safety results from the preceding two-part 24-week double-blind bridging study. During the 24 weeks in the bridging study, ARR decreased from 2.00 to 0.53 in the natalizumab group and from 1.90 to 1.73 in the placebo group \[[@CR8]\]. During the 2-year extension study, ARR remained lower in the previously-on-natalizumab group than in the previously-on-placebo group (0.13 vs. 0.30), and the percentage of relapse-free patients appeared higher in the previously-on-natalizumab group than in the previously-on-placebo group (55% vs. 46%). Thus, slightly better efficacy was observed over the 2 years following the conclusion of the bridging study in patients who received continuous natalizumab treatment than in patients who initiated natalizumab in this extension phase, which suggests an association between earlier initiation of natalizumab and clinical benefits, similar to results seen in non-Asian populations \[[@CR3]\]. However, statistical analysis of this potential relationship was not conducted, as it was considered inappropriate to compare 2 non-randomized groups both receiving natalizumab treatment in the open-label extension study.

Overall, changes in EDSS scores during the extension study were small in both the previously-on-placebo and previously-on-natalizumab groups, consistent with changes observed during the double-blind study \[[@CR8]\]. The trend of EDSS score reduction in both groups and the slightly larger reduction observed in the previously-on-natalizumab group suggest that natalizumab, on average, also prevents disability progression in Japanese patients.

In terms of safety and tolerability, MS relapse and nasopharyngitis were the most frequently reported events in both groups. With MS relapse excluded from the incidence rate of TEAEs, 39 of 43 patients (91%) in the previously-on-placebo group and 52 of 54 patients (96%) in the previously-on-natalizumab group experienced a TEAE. These results were generally similar to the results that included MS relapse as a TEAE.

Although the bridging study was only 24 weeks in duration, similar results were observed: 87% of placebo patients and 72% of natalizumab patients reported ≥1 TEAE, with MS relapse and infections the most commonly reported TEAEs in both groups \[[@CR8]\]. The incidence of testing persistently positive for anti-natalizumab antibodies was 2% (2 of 96 patients in the immunogenicity population) in the extension study, which is slightly lower than the 3--6% incidence that has been reported in non-Asian populations \[[@CR1], [@CR3], [@CR11]\]. One of the two patients who were positive for anti-natalizumab antibodies experienced an infusion reaction, and both patients withdrew from the study. It is difficult to draw conclusions about the relationship between anti-natalizumab antibodies and efficacy or safety in this study, given the small number of patients who were anti-natalizumab antibody-positive. In general, the presence of antibodies against natalizumab has been associated with reduced clinical efficacy, likely due to accelerated clearance of natalizumab and more hypersensitivity and infusion-related reactions, including headache, urticaria, rigors, nausea, vomiting, and flushing \[[@CR14], [@CR15]\].

The risk of developing PML is increased in patients who test positive for anti-JCV antibodies, who have prior immunosuppressant use, and who use natalizumab for \>2 years \[[@CR16]\]. No cases of PML were reported during the 24-week placebo-controlled trial or during year 1 of the open-label extension study.

This study had several key limitations. As the study includes patients from a clinical trial population, the generalizability of these results to the Japanese RRMS patients being treated with natalizumab in real-world settings is unclear. In addition, because the treatment groups in this extension study were not randomized, statistical comparison of efficacy variables was not conducted.

Overall, results from this analysis of efficacy and safety data from patients enrolled in the 2-year open-label extension study of natalizumab were consistent with findings recently reported for patients who received natalizumab during the 24-week double-blind bridging study \[[@CR8]\].

Conclusions {#Sec15}
===========

The efficacy and safety findings from the double-blind bridging study \[[@CR8]\] and the open-label extension study are comparable to and confirm results reported from other clinical trials of natalizumab conducted in non-Asian patient populations \[[@CR1], [@CR2], [@CR17]\], and provide longer-term evidence of the efficacy and safety of natalizumab treatment in Japanese patients with RRMS.
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